Anavex Life Sciences Corp.

AVXL Nasdaq SEC CIK 1314052
Follow Anavex Life Sciences Corp. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income $7.8M +159.1% vs same quarter last year
EPS, diluted $0.08 +150% vs same quarter last year
Operating cash flow −$9.1M +27% vs same quarter last year
Operating income $6.7M +146.6% vs same quarter last year
Net income by quarter
−$11.6M
−$12.1M
−$11.2M
−$13.2M
−$9.8M
−$5.7M
−$5.3M
$7.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
−$60M−$40M−$20M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$46.4M
FY24−$43M
FY23−$47.5M
FY22−$48M
FY21−$37.9M
FY20−$26.3M
FY19−$26.3M
FY18−$17.3M
FY17−$13.5M
FY16−$14.7M
FY15−$12.1M
FY14−$10M
FY13−$3.7M
FY12−$8.3M
FY11−$7.3M